Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methenamine (marketed under the brand name Antihydral) is a topical antiperspirant used for the treatment of excessive sweating (hyperhidrosis), particularly of the hands, feet, and underarms. Developed by Robugen GmbH & Co. KG, the drug functions as a prodrug that releases formaldehyde upon contact with acidic sweat. The released formaldehyde acts by denaturing proteins at the openings of the sweat gland ducts, effectively creating a physical plug that reduces perspiration. It is an established, approved product available in various topical formulations including ointments, creams, and sprays, and has been used for decades in European markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methenamine (Robugen).